Last reviewed · How we verify

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — Portfolio Competitive Intelligence Brief

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tyrosine kinase inhibitor Tyrosine kinase inhibitor phase 3 Tyrosine kinase inhibitor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 1 shared drug class
  2. Angion Biomedica Corp · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
  5. Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
  6. Centre Leon Berard · 1 shared drug class
  7. Chang-Ming Huang, Prof. · 1 shared drug class
  8. AB Science · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest:

Cite this brief

Drug Landscape (2026). Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-f-r-klinische-krebsforschung-ikf-gmbh-at-krankenhaus-nordwest. Accessed 2026-05-17.

Related